SIRT1 deacetylates and enhances KRASMut activity in lung cancer, and inhibiting SIRT1 or activating p300, which acetylates KRASMut, sensitizes tumors to cisplatin and erlotinib, offering a potential combination therapy for KRASMut lung cancer (Shin et al., 2023). This evidence concerns the gene EP300 and lung cancer.